AFP–FcRn Binding Modulation for Immunosuppression-Related Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies fail to effectively modulate alpha-fetoprotein (AFP) levels and activities, particularly in diseases associated with immunosuppression or decreased AFP levels, due to the lack of understanding of AFP's interaction with the neonatal Fc receptor (FcRn).
Innovation Solution
Compositions and methods are developed to inhibit or enhance AFP-FcRn interactions using inhibitors or potentiators, such as antibodies, small molecule compounds, or RNA/DNA aptamers, targeting specific residues on AFP and FcRn to modulate their binding, thereby affecting AFP levels and activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing technologies are used to modulate AFP levels, then AFP levels remain unmodulated, but no effective therapeutic intervention is available
Solution Approach 1:
The patent introduces FcRn as an intermediary mediator that binds to AFP with high affinity, enabling indirect modulation of AFP levels through the FcRn-AFP interaction. This mediator approach allows therapeutic intervention by targeting the FcRn-AFP binding interface with inhibitors or potentiators, rather than directly targeting AFP itself.
Solution Approach 2:
The patent employs parameter changes by modifying the binding affinity between FcRn and AFP through small molecule compounds, antibodies, or aptamers that either inhibit or enhance the interaction. This allows dynamic control of AFP levels by adjusting the binding parameters of the FcRn-AFP complex.
2Reliability
If AFP-FcRn interactions are not targeted, then existing therapies fail, but developing new targeted therapies increases complexity
Solution Approach 1:
The patent extracts the FcRn-AFP interaction as a distinct therapeutic target from the complex system of AFP metabolism and clearance. By isolating this specific interaction, the patent simplifies the therapeutic approach into targeting a single binding interface, reducing overall system complexity while maintaining therapeutic effectiveness.
3Reliability
If AFP levels are not regulated, then immunosuppression-related disorders progress, but developing regulation methods requires new mechanisms
Solution Approach 1:
The patent leverages the universal FcRn receptor, which naturally binds multiple ligands including IgG and albumin, to also bind AFP. This multi-functionality of FcRn provides a pre-existing biological mechanism that can be adapted for AFP regulation, avoiding the need to develop entirely new regulatory mechanisms while enabling disease management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions and methods effectively inhibit or enhance AFP-FcRn interactions, addressing immunosuppression-related disorders by regulating AFP levels, enhancing therapeutic outcomes in cancer and pregnancy-related conditions.
Implementation Method 1
soluble human FcRn binds to AFP with affinities greater than observed with albumin
Implementation Method 2
the binding of FcRn to AFP occurs over a much wider pH range than that observed for IgG and albumin, which typically bind under acidic pH conditions
Data Source
AI summary
As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.